Articles by Philip M. Schneider - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Philip M. Schneider

Establishing a Minimum Incubation Time for Biological Indicators

The authors propose a minimum incubation-time method that provides a means for reproducible determination of biological indicator grow-out time.
Dec 2, 2013

The industry lacks an accepted method for establishing a minimum incubation time (MIT) of less than seven days for biological indicators (BIs). The authors propose an MIT method that provides a means for reproducible determination of BI grow-out time.

Understanding Biological Indicator Grow-Out Times—Part II

In Part II of a series, the authors report on the range and distribution of grow-out times for biological indicators exposed to sublethal sterilization processes.
Jun 2, 2013

The authors report on the range and distribution of grow-out times for biological indicators exposed to sublethal sterilization processes.

Biological Indicator Growout Times: The Impact on Establishing a Reduced Incubation Time Protocol

The authors provide a review of test methodology and standards, including current industry and regulatory proposals, for biological indicator growout times.
May 1, 2012

The authors provide a review of test methodology and standards, including current industry and regulatory proposals, for biological indicator growout times.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here